BRIEF—BeiGene bids to extend Abraxane label in China

BeiGene has applied for Chinese marketing approval for a combination of Abraxane (paclitaxel) and gemcitabine as a first-line treatment for pancreatic cancer.

The company currently markets the product in China as a therapy for breast cancer, under an exclusive license from Celgene.

President Xiaobin Wu said: “Abraxane has been an important global treatment option for patients with metastatic adenocarcinoma of the pancreas outside of China, and we strive to provide access to Abraxane in China to those patients for whom there is great need for additional treatments to combat this deadly disease.”